

Special Issue

The Survival of Colon and Rectal Cancer

Message from the Guest Editor

Colorectal cancer is the third most common cancer in men and the second most common cancer in women. Survival rates have improved due to improved surgical procedures such as total mesorectal excision (TME) and complete mesocolic excision (CME), as well as multidisciplinary approaches, especially for advanced carcinomas. During recent decades, standardisation of treatment has been an important tool to improve survival. Today, with increasing therapeutic options and the results of prognostic factor research, the possibilities to individualise therapy are increasing. Both under- and overtreatment should be avoided. However, not only is the length of survival time important, but also the quality of life of the patients. The aim of this Special Issue is to (a) show the current results of surgical and multidisciplinary treatment of colorectal cancer with regard to recurrence and survival, (b) identify prognostic factors, (c) highlight future possibilities to improve prognosis and (d) discuss individualisation versus standardisation in the treatment of colorectal carcinomas.

Guest Editor

Prof. Dr. Susanne Merkel

Department of General and Visceral Surgery, Friedrich-Alexander-University (FAU) Erlangen-Nuremberg, 91054 Erlangen, Germany

Deadline for manuscript submissions

closed (15 November 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/138191

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)